Human Microbiome Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

The Human Microbiome Market was valued at USD 0.62 Billion in 2024, and is expected to reach USD 1.52 Billion by 2030, rising at a CAGR of 16.28%. The Global Human Microbiome Market is experiencing a significant transformation, fueled by growing scientific recognition of the microbiome's impact on human health and disease, along with increasing investments from pharmaceutical and biotechnology firms. This market encompasses the development of diagnostics, therapeutics, and healthcare solutions aimed at leveraging or modifying the human microbiota comprising trillions of microorganisms that inhabit the human body for improved medical outcomes.

Key Market Drivers

Increased Application in Cancer Treatment

Research has demonstrated that the human microbiome plays a crucial role in modulating immune responses, which directly impacts the efficacy of immunotherapies and chemotherapy. Certain gut microbiota strains have been found to enhance the effectiveness of immune checkpoint inhibitors, leading to improved patient outcomes. Biotech firms and pharmaceutical companies are investing in microbiome-derived drugs that can be used as adjunct therapies to traditional cancer treatments. These therapies aim to reduce treatment-related toxicity, improve drug absorption, and enhance immune system resilience.

The surge in clinical trials exploring microbiome-based interventions for cancer treatment is accelerating market growth. Studies are investigating how gut microbiota composition influences cancer progression and response to therapy. Rajiv Gandhi Cancer Institute and Research Centre (RGCIRC) has established itself as a premier clinical trial site, earning recognition from leading global cancer research institutions and pharmaceutical companies. With a track record of participation in over 300 national and international clinical trials, the center plays a pivotal role in advancing oncology research and innovative cancer therapies across diverse cancer types. Leading biotech firms and research institutions are forming strategic partnerships to develop microbiome-based cancer solutions. Increased funding from government agencies and private investors is driving innovation in microbiome therapeutics.

The integration of microbiome profiling into precision oncology is enabling personalized treatment plans tailored to individual patients. AI-driven microbiome analysis is helping identify biomarkers that predict cancer treatment responses. Regulatory bodies are recognizing the potential of microbiome-based therapies, leading to faster approvals and standardization efforts. The market is witnessing expansion into emerging economies, where cancer prevalence is rising.

Key Market Challenges

Scientific Complexity and Limited Understanding of Microbiome Functions

One of the most fundamental challenges impeding market growth is the incomplete and complex understanding of the human microbiome’s structure, function, and interactions with host physiology. Despite major research advancements, scientists still face difficulties in: Differentiating between beneficial, neutral, and harmful microbes, Understanding causal relationships between microbiome imbalances and specific diseases, Establishing universal biomarkers or reference ranges for “healthy” microbiota.

This scientific uncertainty limits the ability of researchers and companies to design effective, targeted, and reproducible microbiome-based therapies. Moreover, it complicates clinical trial design and makes it harder to validate efficacy, slowing product development and investor confidence.

Key Market Trends

Shift Toward Personalized Microbiome-Based Therapies

The most significant trends fueling market growth is the rapid evolution of personalized medicine powered by microbiome insights. As scientific understanding of the human microbiome deepens, it is becoming increasingly clear that microbial compositions vary significantly across individuals. This has led to a paradigm shift from generalized probiotic or therapeutic approaches toward personalized microbiome interventions, including: Tailored probiotics and synbiotics based on individual gut flora, Microbiome profiling and diagnostics to guide treatment decisions, Customized dietary recommendations to optimize gut health and disease prevention.

This trend aligns with the broader healthcare movement toward precision medicine, offering more effective, safer, and targeted interventions. As genomic sequencing and microbiome mapping technologies become more accessible and affordable, personalized microbiome-based therapies are poised to redefine patient care.

Key Market Players

Enterome Bioscience SA
Yakult Honsha Co. Ltd.
4 D Pharma
Evelo Biosciences
Seres Therapeutics Inc.
Vedanta Biosciences
Second Genome Inc.
Quantibiome
Rebiotix Inc.
Microbiome Therapeutics LLC

Report Scope:

In this report, the Global Human Microbiome Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Human Microbiome Market, By Product:

Prebiotics
Probiotics
Medical Food
Supplements
Others

Human Microbiome Market, By Application:

Therapeutic
Diagnostic

Human Microbiome Market, By Disease:

Infectious Disease
Endocrine and Metabolic Disorders
Gastrointestinal Diseases
Cancer
Others

Human Microbiome Market, By Technology:

Genomics
Proteomics
Metabolomics

Human Microbiome Market, By Type:

FMT
Peptide
Live Biotherapeutic Product
Others

Human Microbiome Market, By Region:

North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Human Microbiome Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.

Company Information

Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Human Microbiome Market Outlook

5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product (Prebiotics, Probiotics, Medical Food, Supplements, Others)
5.2.2. By Application (Therapeutic, Diagnostic)
5.2.3. By Disease (Infectious Disease, Endocrine and Metabolic Disorders, Gastrointestinal Diseases, Cancer, Others)
5.2.4. By Technology (Genomics, Proteomics, Metabolomics)
5.2.5. By Type (FMT, Peptide, Live Biotherapeutic Product, Others)
5.2.6. By Region
5.2.7. By Company (2024)
5.3. Market Map

6. North America Human Microbiome Market Outlook

6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product
6.2.2. By Application
6.2.3. By Disease
6.2.4. By Technology
6.2.5. By Type
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States Human Microbiome Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product
6.3.1.2.2. By Application
6.3.1.2.3. By Disease
6.3.1.2.4. By Technology
6.3.1.2.5. By Type
6.3.2. Canada Human Microbiome Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product
6.3.2.2.2. By Application
6.3.2.2.3. By Disease
6.3.2.2.4. By Technology
6.3.2.2.5. By Type
6.3.3. Mexico Human Microbiome Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product
6.3.3.2.2. By Application
6.3.3.2.3. By Disease
6.3.3.2.4. By Technology
6.3.3.2.5. By Type

7. Europe Human Microbiome Market Outlook

7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Application
7.2.3. By Disease
7.2.4. By Technology
7.2.5. By Type
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Human Microbiome Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product
7.3.1.2.2. By Application
7.3.1.2.3. By Disease
7.3.1.2.4. By Technology
7.3.1.2.5. By Type
7.3.2. United Kingdom Human Microbiome Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product
7.3.2.2.2. By Application
7.3.2.2.3. By Disease
7.3.2.2.4. By Technology
7.3.2.2.5. By Type
7.3.3. Italy Human Microbiome Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product
7.3.3.2.2. By Application
7.3.3.2.3. By Disease
7.3.3.2.4. By Technology
7.3.3.2.5. By Type
7.3.4. France Human Microbiome Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product
7.3.4.2.2. By Application
7.3.4.2.3. By Disease
7.3.4.2.4. By Technology
7.3.4.2.5. By Type
7.3.5. Spain Human Microbiome Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product
7.3.5.2.2. By Application
7.3.5.2.3. By Disease
7.3.5.2.4. By Technology
7.3.5.2.5. By Type

8. Asia-Pacific Human Microbiome Market Outlook

8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Application
8.2.3. By Disease
8.2.4. By Technology
8.2.5. By Type
8.2.6. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Human Microbiome Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product
8.3.1.2.2. By Application
8.3.1.2.3. By Disease
8.3.1.2.4. By Technology
8.3.1.2.5. By Type
8.3.2. India Human Microbiome Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product
8.3.2.2.2. By Application
8.3.2.2.3. By Disease
8.3.2.2.4. By Technology
8.3.2.2.5. By Type
8.3.3. Japan Human Microbiome Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product
8.3.3.2.2. By Application
8.3.3.2.3. By Disease
8.3.3.2.4. By Technology
8.3.3.2.5. By Type
8.3.4. South Korea Human Microbiome Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product
8.3.4.2.2. By Application
8.3.4.2.3. By Disease
8.3.4.2.4. By Technology
8.3.4.2.5. By Type
8.3.5. Australia Human Microbiome Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product
8.3.5.2.2. By Application
8.3.5.2.3. By Disease
8.3.5.2.4. By Technology
8.3.5.2.5. By Type

9. South America Human Microbiome Market Outlook

9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product
9.2.2. By Application
9.2.3. By Disease
9.2.4. By Technology
9.2.5. By Type
9.2.6. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Human Microbiome Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product
9.3.1.2.2. By Application
9.3.1.2.3. By Disease
9.3.1.2.4. By Technology
9.3.1.2.5. By Type
9.3.2. Argentina Human Microbiome Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product
9.3.2.2.2. By Application
9.3.2.2.3. By Disease
9.3.2.2.4. By Technology
9.3.2.2.5. By Type
9.3.3. Colombia Human Microbiome Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product
9.3.3.2.2. By Application
9.3.3.2.3. By Disease
9.3.3.2.4. By Technology
9.3.3.2.5. By Type

10. Middle East and Africa Human Microbiome Market Outlook

10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product
10.2.2. By Application
10.2.3. By Disease
10.2.4. By Technology
10.2.5. By Type
10.2.6. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Human Microbiome Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product
10.3.1.2.2. By Application
10.3.1.2.3. By Disease
10.3.1.2.4. By Technology
10.3.1.2.5. By Type
10.3.2. Saudi Arabia Human Microbiome Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product
10.3.2.2.2. By Application
10.3.2.2.3. By Disease
10.3.2.2.4. By Technology
10.3.2.2.5. By Type
10.3.3. UAE Human Microbiome Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product
10.3.3.2.2. By Application
10.3.3.2.3. By Disease
10.3.3.2.4. By Technology
10.3.3.2.5. By Type

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. Global Human Microbiome Market: SWOT Analysis

14. Competitive Landscape

14.1. Enterome Bioscience SA
14.1.1. Business Overview
14.1.2. Product & Service Offerings
14.1.3. Recent Developments
14.1.4. Financials (If Listed)
14.1.5. Key Personnel
14.1.6. SWOT Analysis
14.2. Yakult Honsha Co. Ltd.
14.3. 4 D Pharma
14.4. Evelo Biosciences
14.5. Seres Therapeutics Inc.
14.6. Vedanta Biosciences
14.7. Second Genome Inc.
14.8. Quantibiome
14.9. Rebiotix Inc.
14.10. Microbiome Therapeutics LLC

15. Strategic Recommendations16. About the Publisher & Disclaimer

Companies Mentioned

Enterome Bioscience SA
Yakult Honsha Co. Ltd.
4 D Pharma
Evelo Biosciences
Seres Therapeutics Inc.
Vedanta Biosciences
Second Genome Inc.
Quantibiome
Rebiotix Inc.
Microbiome Therapeutics LLC

Table Information

Report Attribute	Details
No. of Pages	182
Published	August 2025
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 0.62 Billion
Forecasted Market Value ( USD ) by 2030	$ 1.52 Billion
Compound Annual Growth Rate	16.2%
Regions Covered	Global
No. of Companies Mentioned	10

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€3995EUR$4,500USD£3,466GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€4883EUR$5,500USD£4,236GBP